Biologic actions and pharmacokinetic studies of auranofin.
The preclinical profiles of auranofin (Ridaura), an oral chrysotherapeutic agent, parenteral gold sodium thiomalate, gold thioglucose, and their respective ligands were compared. Auranofin was more effective than gold sodium thiomalate in suppressing inflammation and stimulating cell-mediated immunity. In contrast to gold sodium thiomalate and gold thioglucose, auranofin inhibited cellular release of lysosomal enzymes, antibody-dependent cellular cytotoxicity, production of antibodies in adjuvant arthritic rats, and antibodies involved in cytotoxicity reactions. The respective ligands were without significant biologic activity. In rats, a higher fraction of gold was associated with blood cells after auranofin administration than after gold sodium thiomalate. The absorption, distribution, metabolism, and excretion of auranofin are uniquely different from other gold compounds.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000378:metabolism / Q000494:pharmacology*; D000917:Antibody Formation / Q000187:drug effects; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000276:immunology; D001310:Auranofin; D006051:Aurothioglucose / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D004487:Edema / Q000188:drug therapy; D005260:Female; D006046:Gold / Q000031:analogs & derivatives*; D006052:Gold Sodium Thiomalate / Q000378:metabolism / Q000494:pharmacology; D007111:Immunity, Cellular / Q000187:drug effects; D007700:Kinetics; D008024:Ligands; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009504:Neutrophils / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D013481:Superoxides / Q000096:biosynthesis; D014018:Tissue Distribution
D000893:Anti-Inflammatory Agents; D008024:Ligands; D013481:Superoxides; D006052:Gold Sodium Thiomalate; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold